Search

Your search keyword '"Chartier, Loic"' showing total 7 results
Start Over Author "Chartier, Loic" Publisher american society of hematology
7 results on '"Chartier, Loic"'

1. Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis

Author

Thieblemont, Catherine, primary, Altmann, Bettina, additional, Frontzek, Fabian, additional, Renaud, Loïc, additional, Chartier, Loic, additional, Ketterer, Nicolas, additional, Récher, Christian, additional, Poeschel, Viola, additional, Fitoussi, Olivier, additional, Held, Gerhard, additional, Casasnovas, Olivier, additional, Haioun, Corinne, additional, Morschhauser, Franck, additional, Glass, Bertram, additional, Mounier, Nicolas, additional, Tilly, Herve, additional, Rosenwald, Andreas, additional, Ott, German, additional, Lenz, Georg, additional, Molina, Thierry, additional, Ziepert, Marita, additional, and Schmitz, Norbert, additional

Published
2023
Full Text
View/download PDF

2. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA

Author

Aubrais, Raphaelle, primary, Bouabdallah, Krimo, additional, chartier, loic, additional, Herbaux, Charles, additional, Banos, Anne, additional, Brice, Pauline, additional, Sibon, David, additional, Schiano, Jean Marc, additional, Cluzeau, Thomas, additional, Laribi, Kamel, additional, LE CALLOCH, Ronan, additional, bellal, Mathieu, additional, Delapierre, Baptiste, additional, daguindau, nicolas, additional, Amorim, Sandy, additional, Agbetiafa, Kossi, additional, Chauchet, Adrien, additional, besson, caroline, additional, Durot, Eric, additional, Bonnet, Christophe, additional, Fouillet, Ludovic, additional, Bijou, Fontanet, additional, Tournilhac, Olivier, additional, Gaulard, Philippe, additional, Parrens, Marie-Cécile, additional, and Damaj, Gandhi, additional

Published
2022
Full Text
View/download PDF

3. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma

Author

Thieblemont, Catherine, primary, Chartier, Loic, additional, Dührsen, Ulrich, additional, Vitolo, Umberto, additional, Barrington, Sally F., additional, Zaucha, Jan M., additional, Vercellino, Laetitia, additional, Gomes Silva, Maria, additional, Patrocinio-Carvalho, Ines, additional, Decazes, Pierre, additional, Viailly, Pierre-Julien, additional, Tilly, Herve, additional, Berriolo-Riedinger, Alina, additional, Casasnovas, Oliver, additional, Hüttmann, Andreas, additional, Ilyas, Hajira, additional, Mikhaeel, N. George, additional, Dunn, Joel, additional, Cottereau, Anne-Ségolène, additional, Schmitz, Christine, additional, Kostakoglu, Lale, additional, Paulson, Joseph N., additional, Nielsen, Tina, additional, and Meignan, Michael, additional

Published
2022
Full Text
View/download PDF

4. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Author

Le Gouill, Steven, primary, Ghesquières, Hervé, additional, Oberic, Lucie, additional, Morschhauser, Franck, additional, Tilly, Hervé, additional, Ribrag, Vincent, additional, Lamy, Thierry, additional, Thieblemont, Catherine, additional, Maisonneuve, Hervé, additional, Gressin, Rémy, additional, Bouhabdallah, Krimo, additional, Haioun, Corinne, additional, Damaj, Gandhi, additional, Fornecker, Luc, additional, Bouhabdallah, Réda, additional, Feugier, Pierre, additional, Sibon, David, additional, Cartron, Guillaume, additional, Bonnet, Christophe, additional, André, Marc, additional, Chartier, Loic, additional, Ruminy, Philippe, additional, Kraeber-Bodéré, Françoise, additional, Bodet-Milin, Caroline, additional, Berriolo-Riedinger, Alina, additional, Brière, Josette, additional, Jais, Jean-Philippe, additional, Molina, Thierry Jo, additional, Itti, Emmanuel, additional, and Casasnovas, René-Olivier, additional

Published
2021
Full Text
View/download PDF

5. High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Author

Vercellino, Laetitia, primary, Cottereau, Anne-Segolene, primary, Casasnovas, Olivier, primary, Tilly, Hervé, primary, Feugier, Pierre, primary, Chartier, Loic, primary, Fruchart, Christophe, primary, Roulin, Louise, primary, Oberic, Lucie, primary, Pica, Gian Matteo, primary, Ribrag, Vincent, primary, Abraham, Julie, primary, Simon, Marc, primary, Gonzalez, Hugo, primary, Bouabdallah, Reda, primary, Fitoussi, Olivier, primary, Sebban, Catherine, primary, López-Guillermo, Armando, primary, Sanhes, Laurence, primary, Morschhauser, Franck, primary, Trotman, Judith, primary, Corront, Bernadette, primary, Choufi, Bachra, primary, Snauwaert, Sylvia, primary, Godmer, Pascal, primary, Briere, Josette, primary, Salles, Gilles, primary, Gaulard, Philippe, primary, Meignan, Michel, primary, and Thieblemont, Catherine, primary

Published
2020
Full Text
View/download PDF

6. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Author

Cottereau, Anne-Ségolène, primary, Versari, Annibale, additional, Loft, Annika, additional, Casasnovas, Olivier, additional, Bellei, Monica, additional, Ricci, Romain, additional, Bardet, Stéphane, additional, Castagnoli, Antonio, additional, Brice, Pauline, additional, Raemaekers, John, additional, Deau, Bénédicte, additional, Fortpied, Catherine, additional, Raveloarivahy, Tiana, additional, Van Zele, Emelie, additional, Chartier, Loic, additional, Vander Borght, Thierry, additional, Federico, Massimo, additional, Hutchings, Martin, additional, Ricardi, Umberto, additional, Andre, Marc, additional, and Meignan, Michel, additional

Published
2018
Full Text
View/download PDF

7. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.

Author

Aubrais R, Bouabdallah K, Chartier L, Herbaux C, Banos A, Brice P, Sibon D, Schiano JM, Cluzeau T, Laribi K, Le Calloch R, Bellal M, Delapierre B, Daguindau N, Amorim S, Agbetiafa K, Chauchet A, Besson C, Durot E, Bonnet C, Fouillet L, Bijou F, Tournilhac O, Gaulard P, Parrens MC, and Damaj G

Subjects
Humans, Brentuximab Vedotin therapeutic use, Bendamustine Hydrochloride therapeutic use, Retrospective Studies, Salvage Therapy, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasm Recurrence, Local drug therapy, Chronic Disease, Lymphoma, T-Cell, Peripheral drug therapy, Hodgkin Disease drug therapy
Abstract

Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients., (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results